Literature DB >> 16565142

Prophylactic heparin in palliative care: ...to a challenging idea.

John C Chambers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16565142      PMCID： PMC1410878          DOI： 10.1136/bmj.332.7543.729

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  2 in total

1.  Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study.

Authors:  S I R Noble; A Nelson; C Turner; I G Finlay
Journal:  BMJ       Date:  2006-02-03

2.  Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

Authors:  Ajay K Kakkar; Mark N Levine; Zbigniew Kadziola; Nicholas R Lemoine; Vanessa Low; Heman K Patel; Gordon Rustin; Michael Thomas; Mary Quigley; Robin C N Williamson
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544
  2 in total
  2 in total

Review 1.  Decision making about change of medication for comorbid disease at the end of life: an integrative review.

Authors:  Ronald T C M van Nordennen; Jan C M Lavrijsen; Kris C P Vissers; Raymond T C M Koopmans
Journal:  Drugs Aging       Date:  2014-07       Impact factor: 3.923

Review 2.  Thromboprophylaxis in the End-of-Life Cancer Care: The Update.

Authors:  Ewa Zabrocka; Ewa Sierko
Journal:  Cancers (Basel)       Date:  2020-03-05       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.